GenMark Diagnostics Reports Q3 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
GenMark Diagnostics (GNMK) Announces Another ePlex Delay; Canaccord Genuity Cuts Price Target to $8
October 28, 2015 11:02 AM EDTCanaccord Genuity maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $8.00 (from $14.00), following the announcement of another delay on ePlex. GNMK cited their need to redesign plastic-injected parts to 2 components of their cartridge. GNMK pushed out its timelines by another quarter,... More
GenMark Diagnostics (GNMK) Pushes ePlex Launch to 2016; Needham & Company Cuts Price Target to $13
October 28, 2015 7:11 AM EDTNeedham & Company maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $13.00 (from $16.00), following the company's 3Q15 earnings results. Revenue was $8.5M vs. consensus of $8.2M and GAAP EPS was ($0.27) vs. consensus of ($0.31). Management now believes that the launch of the sample-to-answer... More
